Date: 2017-02-28
Type of information: Clinical trial authorisation
phase: 1
Announcement: clinical trial authorization
Company: Melinta Therapeutics (USA - CT)
Product: radezolid
Action mechanism: antibiotic. Radezolid is a second-generation oxazolidinone discovered by Melinta scientists using proprietary, structure-based design, to achieve higher ribosomal binding affinity, minimal off-target activity, and a broader spectrum of antimicrobial activity than is currently available in the class.
Disease: mild-to-moderate acne
Therapeutic area: Dermatological diseases
Country:
Trial details:
Latest news: In May 2017, Phase 1 studies were initiated to study radezolid for the treatment of acne vulgaris. • On February 28, 2017, Melinta Therapeutics announced that the FDA has accepted an Investigational New Drug (IND) application for topical radezolid for the treatment of mild-to-moderate acne. Melinta and an undisclosed partner are collaborating on the development of radezolid for the treatment of dermatological conditions including acne under a December 2014 agreement. Since that time, the companies have successfully developed a formulation and completed IND-enabling preclinical development. Melinta and its partner will be collaborating on designing the clinical development plan, and anticipate initiating a Phase 1 clinical trial in early 2017.
